期刊
INTERNAL MEDICINE
卷 57, 期 23, 页码 3429-3432出版社
JAPAN SOC INTERNAL MEDICINE
DOI: 10.2169/internalmedicine.0999-18
关键词
erlotinib; afatinib; EGFR mutation; squamous cell carcinoma transformation
资金
- Japan Society for the Promotion of Science [26670416, 26293197]
Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second- or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据